STRO compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

STROSutro Biopharma, Inc.

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

STROSutro Biopharma, Inc.

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

STRO1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±20.6%▼−14.94%×0.72

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±3.7%▲+3.73%×1.00

Q2 FY26±4.1%▲+4.57%×1.12

= impliedSTRO realized, solidAMGN realized, hatchedOne scale, both sides: full bar = 21%× = |realized| ÷ impliedSource: market data

Q1 FY26

±3.9%

▼−4.75%

×1.23

Feb 4 '26±3.7%▲+8.15%×2.22

STROSutro Biopharma, Inc.

9.63▲+4.71%· post 9.63

Mkt cap$159.5MRevenue$10MQ2 FY26Revenue$102MFY25

AMGNAmgen Inc

460.55▲+0.06%· post 460.42

ClosedNov 6 '26

Mkt cap$249.0BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

Compare

ClosedNov 6 '26

STROSutro Biopharma, Inc.

AMGNAmgen Inc

9.63▲+4.71%post 9.63

Price

460.55▲+0.06%post 460.42

$159.5M

Mkt cap

$249.0B

Q2 FY26$10M

Revenue

$10.4BQ3 FY26

FY25$102M

Revenue

$36.8BFY25

STRO9.63▲+4.71%vsAMGN460.55▲+0.06%ClosedNov 6 '26